Research into the management of PE identified two novel selective NaV1.7 blockers, PF-05089771 and TV-45070, which may hold promise in ameliorating pain symptoms associated with PE [85] and viral-induced neuropathies. This evidence concerns the gene SCN9A and neuropathy.